Company Overview of Synageva BioPharma Corp.
Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL) under the Kanuma brand name for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy in a Phase 1/2 study for lysosomal storage disease, known as mucopolysaccharidosis type IIIB; SBC-105, an enzyme replacement therapy in preclinical...
33 Hayden Avenue
Lexington, MA 02421
Founded in 1996
Key Executives for Synageva BioPharma Corp.
Chief Executive Officer, President and Secretary
Chief Financial Officer and Senior Vice President
Chief Medical Officer, Head of Research & Development and Executive Vice President
Chief Legal Officer, Senior Vice President and General Counsel
Senior Vice President of Finance & Business Operations
Compensation as of Fiscal Year 2015.
Synageva BioPharma Corp. Key Developments
Synageva Biopharma Corp. Announces Resignation of Directors
Jun 23 15
Alexion Pharmaceuticals Inc. announced acquisition of Synageva BioPharma Corp. In connection with the first merger and as contemplated by the merger agreement, Michael V. Greco, became the sole director of the company. In connection therewith, each of Felix J. Baker, Stephen R. Biggar, Stephen R. Davis, Thomas R. Malley, Sanj K. Patel, Barry D. Quart, Thomas J. Tisch and Peter Wirth tendered their respective resignations as directors from the board of directors of the company and from all committees of the Board on which such directors served, effective as of the effective time.
Synageva BioPharma Corp.(NasdaqGS:GEVA) dropped from NASDAQ Composite Index
Jun 23 15
Synageva BioPharma Corp. will be removed from Nasdaq Composite Index.
Synageva BioPharma Corp.(NasdaqGS:GEVA) dropped from NASDAQ Biotechnology Index
Jun 21 15
Synageva BioPharma Corp. will be removed from NASDAQ Biotech Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 6, 2015
Most Searched Private Companies
Sponsored Financial Commentaries